SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluidigm (NASDAQ:FLDM) announced the availability of Single-Cell ATAC-seq, an epigenetics app for the C1 system, that allows researchers to explore the regulatory systems that drive cellular function.